Powars D., Wilson B., Imbus C., et al.The natural history of stroke in sickle cell disease. Am J Med1978;65:461-70.
2.
Sarnaik SA, Lusher JMNeurological complications of sickle cell anemia. Am J Pediatr Hematol Oncol1982;4:386-94.
3.
Russell MO, Goldberg HI, Hodson A., et al. Effect of transfusion therapy on arteriographic abnormalities and on recurrence of stroke in sickle cell disease. Blood1984;63:162-9.
4.
Wilimas J., Goff JR, Anderson HR, et al. Efficacy of transfusion therapy for one to two years in patients with sickle cell disease and cerebrovascular accidents. J Pediatr1980;96:205-8.
5.
Moohr JW, Wilson H., Pang EJStokes and their management in sickle cell disease. In: Fried W, ed. Comparative Clinical Aspects of Sickle Cell Disease. Amsterdam: Elsevier North Holland, 1982;101-11.
6.
Evatt BL, Gomperts ED, McDougal SJ, et al. Coincidental appearance of LAV/HTLV III antibodies in hemophiliacs at the onset of the AIDS epidemic. N Engl J Med1985;312:483-6.
7.
Gill JC, Menitove JE, Anderson PR, et al. HTLV-III serology in hemophilia: Relationship with immunologic abnormalities. J Pediatr1986;108:511-6.
8.
Bove JRTransfusion-associated hepatitis and AIDS. What is the risk?N Engl J Med1987;317:242-5.
9.
Gomperts EDProcedures for the inactivation of viruses in clotting factor concentrates . Am J Hematol1986 ;23:295-305.
10.
Kernoff Pba, Lee CA, Karayiammis P., et al.High risk of non-A, non-B hepatitis after a first exposure to volunteer or commercial clotting factor concentrate: Effects of prophylactic immune serum globulin. Br J Haematol1985;60:469-79.
11.
Aach RD, Szmuness W., Moskey JW, et al. Serum alanine aminotransferase in donors in relation to the risk of non-A, non-B hepatitis in recipients. N Engl J Med1981; 304:989-94.
12.
Pauker SG, Kassirer JPDecision analysis. N Engl J Med1987 ;316:250-8.
13.
Bussel JB, Goldman A., Imbach P., et al. Treatment of acute idiopathic thrombocytopenia of childhood with intravenous gammaglobulin. J Pediatr1985;106:886-90.